CO7131358A2 - Compuestos de n-alquiltriazol como antagonistas de lpar - Google Patents

Compuestos de n-alquiltriazol como antagonistas de lpar

Info

Publication number
CO7131358A2
CO7131358A2 CO14256136A CO14256136A CO7131358A2 CO 7131358 A2 CO7131358 A2 CO 7131358A2 CO 14256136 A CO14256136 A CO 14256136A CO 14256136 A CO14256136 A CO 14256136A CO 7131358 A2 CO7131358 A2 CO 7131358A2
Authority
CO
Colombia
Prior art keywords
compounds
alkyltriazole
lpar antagonists
lpar
antagonists
Prior art date
Application number
CO14256136A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7131358(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO7131358A2 publication Critical patent/CO7131358A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO14256136A 2012-06-20 2014-11-21 Compuestos de n-alquiltriazol como antagonistas de lpar CO7131358A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CO7131358A2 true CO7131358A2 (es) 2014-12-01

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14256136A CO7131358A2 (es) 2012-06-20 2014-11-21 Compuestos de n-alquiltriazol como antagonistas de lpar

Country Status (22)

Country Link
US (1) US9321738B2 (instruction)
EP (1) EP2864300A1 (instruction)
JP (1) JP2015520202A (instruction)
KR (1) KR20150021057A (instruction)
CN (1) CN104411692A (instruction)
AU (1) AU2013279512A1 (instruction)
BR (1) BR112014030685A2 (instruction)
CA (1) CA2869541A1 (instruction)
CL (1) CL2014003243A1 (instruction)
CO (1) CO7131358A2 (instruction)
CR (1) CR20140525A (instruction)
EA (1) EA201492285A1 (instruction)
HK (1) HK1206342A1 (instruction)
IL (1) IL236088A0 (instruction)
IN (1) IN2014DN09348A (instruction)
MA (1) MA37764A1 (instruction)
MX (1) MX2014014710A (instruction)
PE (1) PE20142448A1 (instruction)
PH (1) PH12014502789A1 (instruction)
SG (1) SG11201407220YA (instruction)
UA (1) UA109868C2 (instruction)
WO (1) WO2013189864A1 (instruction)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト
HK1206339A1 (en) * 2012-06-20 2016-01-08 霍夫曼-拉罗奇有限公司 N-aryltriazole compounds as lpar antagonists
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
KR102433588B1 (ko) 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
WO2019126089A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
BR112020012177A2 (pt) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company azóis triazóis do ácido ciclo-hexílico como antagonistas de lpa
CN112055711B (zh) * 2017-12-19 2024-07-23 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑吖嗪类
EP3728209A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
WO2019126090A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7256807B2 (ja) * 2017-12-19 2023-04-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
EP3728216B1 (en) 2017-12-19 2023-09-06 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112041316B (zh) * 2017-12-19 2024-11-22 百时美施贵宝公司 作为lpa拮抗剂的异噁唑o-连接的氨基甲酰基环己基酸
AU2018395275A1 (en) * 2017-12-29 2020-07-16 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN113366000A (zh) * 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
JP7429224B2 (ja) * 2018-09-18 2024-02-07 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘプチル酸
CA3158743A1 (en) * 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7701473B2 (ja) 2021-05-11 2025-07-01 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
US20220411406A1 (en) * 2021-05-13 2022-12-29 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PH12013501136A1 (en) * 2010-12-07 2013-07-08 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2014525932A (ja) * 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト

Also Published As

Publication number Publication date
US20150133511A1 (en) 2015-05-14
WO2013189864A1 (en) 2013-12-27
CR20140525A (es) 2015-01-12
IL236088A0 (en) 2015-02-01
SG11201407220YA (en) 2014-12-30
MX2014014710A (es) 2015-03-04
CL2014003243A1 (es) 2015-03-20
EA201492285A1 (ru) 2015-04-30
EP2864300A1 (en) 2015-04-29
JP2015520202A (ja) 2015-07-16
US9321738B2 (en) 2016-04-26
PH12014502789A1 (en) 2015-02-09
CN104411692A (zh) 2015-03-11
HK1206342A1 (en) 2016-01-08
IN2014DN09348A (instruction) 2015-07-17
KR20150021057A (ko) 2015-02-27
CA2869541A1 (en) 2013-12-27
MA37764A1 (fr) 2016-01-29
AU2013279512A1 (en) 2014-10-16
BR112014030685A2 (pt) 2017-06-27
UA109868C2 (ru) 2015-10-12
PE20142448A1 (es) 2015-01-28

Similar Documents

Publication Publication Date Title
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
CL2014001174A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
DOP2014000152A (es) Inhibidores de bromodominios
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
CU20150021A7 (es) Piridinonas bicíclicas novedosas
ECSP14013215A (es) Compuestos novedosos
ECSP16074478A (es) Compuestos novedosos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
CU20100210A7 (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas